The abstract is read at the publisher; the summary is JClub's.
Lithium is linked to fewer completed suicides in psychiatric-disorder randomized trials (OR=0.39, 95% CI=0.15–1.00; I²=0%), but the effect is null-inclusive and estimator-sensitive.
- Why it matters: Earlier quantitative syntheses diverged, leaving uncertainty about lithium’s suicide-prevention benefit across suicide-related outcomes in psychiatric patients.
- What they did: The authors re-extracted eligible randomized evidence from systematic reviews and updated primary-trial searches (to April 6, 2026; updated search from January 2024), pooling prespecified outcomes with Mantel-Haenszel ORs and GRADE certainty.
- The result: Completed-suicide findings favored lithium but varied by sensitivity (Peto OR=0.42, 95% CI=0.18–0.98; influential-comparison exclusion OR=0.43, 95% CI=0.13–1.40), with a subgroup signal in mixed mood-disorder trials (OR=0.25, 95% CI=0.07–0.90) and no consistent effects for other suicide-related outcomes; certainty was low to very low.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.